Polyrizon (PLRZ) announced the appointment of Dr. Michal Meir, Senior Consultant at MedTech, as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company’s preparations towards its clinical trial for PL-14 that is expected to commence in 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRZ:
- Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial
- Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker
- Opening Day: Heritage Distilling, Dynamix open for trading
- Opening Day: Polyrizon, Gelteq debut in quiet IPO week
- Polyrizon 959K share IPO priced at $4.38